TY - JOUR
T1 - The genetics of frontotemporal lobar degeneration
AU - Rademakers, Rosa
AU - Hutton, Mike
N1 - Funding Information:
The authors wish to acknowledge and thank the families who contributed samples that were critically important to past, present and future research. Our work was supported by NIH grants P01 AG017216 and R01 AG026251, the Mayo Clinic ADRC (P50 AG16574, R. Petersen, PI; to MH), The Mayo Clinic Research Foundation and the Robert and Clarice Smith Fellowship program. RR is a postdoctoral fellow of the Fund for Scientific Research Flanders (FWO-F).
PY - 2007/9
Y1 - 2007/9
N2 - The clinical disorders associated with frontotemporal lobar degeneration (FTLD) are increasingly recognized as an important cause of early-onset dementia. Patients usually present with progressive changes in personality, behavior, or language, progressing to general cognitive impairment and ultimately death. In the past decade, improved clinical and histopathologic characterization uncovered extensive heterogeneity, and multiple clinical and pathologic FTLD subtypes were defined. Simultaneously, the discovery of four causal FTLD genes emphasized the genetic complexity associated with FTLD. More recently, the field of FTLD has gained increased attention as a result of two major findings. First, mutations in the progranulin gene (PGRN) were recognized as a major cause of FTLD with ubiquitin-positive and tau-negative inclusions (FTLD-U), and subsequently the TAR DNA-binding protein-43 (TDP-43) was identified as a key protein within the ubiquitinated inclusions in FTLD-U and amyotrophic lateral sclerosis (ALS). In this report, we outline the progress made in the study of the genetic etiologies and neuropathologic substrates in FTLD.
AB - The clinical disorders associated with frontotemporal lobar degeneration (FTLD) are increasingly recognized as an important cause of early-onset dementia. Patients usually present with progressive changes in personality, behavior, or language, progressing to general cognitive impairment and ultimately death. In the past decade, improved clinical and histopathologic characterization uncovered extensive heterogeneity, and multiple clinical and pathologic FTLD subtypes were defined. Simultaneously, the discovery of four causal FTLD genes emphasized the genetic complexity associated with FTLD. More recently, the field of FTLD has gained increased attention as a result of two major findings. First, mutations in the progranulin gene (PGRN) were recognized as a major cause of FTLD with ubiquitin-positive and tau-negative inclusions (FTLD-U), and subsequently the TAR DNA-binding protein-43 (TDP-43) was identified as a key protein within the ubiquitinated inclusions in FTLD-U and amyotrophic lateral sclerosis (ALS). In this report, we outline the progress made in the study of the genetic etiologies and neuropathologic substrates in FTLD.
UR - http://www.scopus.com/inward/record.url?scp=34548737197&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=34548737197&partnerID=8YFLogxK
U2 - 10.1007/s11910-007-0067-6
DO - 10.1007/s11910-007-0067-6
M3 - Review article
C2 - 17764635
AN - SCOPUS:34548737197
SN - 1528-4042
VL - 7
SP - 434
EP - 442
JO - Current Neurology and Neuroscience Reports
JF - Current Neurology and Neuroscience Reports
IS - 5
ER -